@phdthesis{oai:kagawa-u.repo.nii.ac.jp:02000052,
 author = {村澤, 千沙 and Murazawa, Chisa},
 month = {2023-10-02, 2023-10-02, 2023-10-02},
 note = {The immune response to cancer serves an important role in disease progression and patient prognosis. For triple‑negative breast cancer showing aggressive behavior, immunotherapy has a good efficacy because of the potent immunogenicity of this type of cancer. However, the dominant subtype, luminal human epidermal growth factor receptor‑2 (HER2)‑negative breast cancer, is less immunogenic. To determine whether luminal HER2‑negative cancer reacts to the anticancer immune response, the present study analyzed the status and prognostic value of the principal immunological biomarkers of breast cancer, including tumor‑infiltrating lymphocytes (TILs), CD8+ T lymphocytes, the major histocompatibility complex and programmed cell death ligand‑1 (PD‑L1). The biomarkers were compared between patients with luminal HER2‑negative breast cancer and those with immunogenic subtypes including triple‑negative and HER2‑overexpressed breast cancer. A total of 71 patients with primary breast cancer were classified into the immunogenic non‑luminal (n=23) and less immunogenic luminal HER2‑negative groups (n=48) based on immunogenicity. In the luminal HER2‑negative group, compared with patients with low TIL levels, those with high TIL levels were at an advanced stage of cancer (P=0.024) and showed worse relapse‑free survival (P=0.057); however, the remaining biomarkers exhibited no association with cancer progression or prognosis. In the non‑luminal group, patients with high TIL levels showed significantly better RFS than those with low TIL levels (P=0.014). Compared with non‑luminal patients negative for PD‑L1, those positive for PD‑L1 exhibited better overall survival (P=0.064). Notably, TIL status was found to exhibit contrasting prognostic predictions based on immunogenicity. In conclusion, TILs are a strong candidate for prognostic prediction in breast cancer, regardless of the subtype. PD‑L1 is a potential candidate for prognostic prediction in immunogenic breast cancers, but not in the luminal HER2‑negative subtype.},
 school = {香川大学, Kagawa University},
 title = {Status and prognostic value of immunological biomarkers of breast cancer},
 year = {},
 yomi = {ムラザワ, チサ}
}